echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Cui Jisong and Shi Yigong co-founded, Nuocheng Jianhua declares for IPO on the Sci-tech Innovation Board!

    Cui Jisong and Shi Yigong co-founded, Nuocheng Jianhua declares for IPO on the Sci-tech Innovation Board!

    • Last Update: 2021-09-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Guide: Dr.


    Introduction:

    During the reporting period, the company invested a large amount of funds for pre-clinical research, clinical trials and preparation of new drugs for the product pipeline


    4.


    The company is an innovative biopharmaceutical company with excellent independent research and development capabilities as its core driving force.


    The company has a founding team and a management team with international innovation vision and deep industry insights


    Under the leadership of a management team with rich experience in R&D, production and commercialization, the company has built an integrated biomedical platform, taking into account the needs of R&D quality and R&D speed, and has established a high balance of innovation and risk, covering multiple poles.


    The company's product layout focuses on tumors and autoimmune diseases with a broad market space, and focuses on building innovative therapies with synergistic effects


    In terms of new drug discovery and development, the company has always adhered to independent innovation as the engine of sustainable development, and has built a compound optimization platform, a drug crystal form research platform, and a research and industrialization platform for insoluble drug solubilization preparation technology: (1) Compounds The optimization platform can accelerate the discovery of highly druggable compounds based on the three-dimensional crystal structure of protein-drug molecules; (2) The drug crystal form research platform can be used to determine the drug substance with dominant crystal forms and support stability studies; (3) Insoluble The research and development and industrialization platform of drug solubilizing preparation technology can solve the bottleneck problem of the current formulations that are common in innovative drugs, and effectively increase the bioavailability of candidate drugs


    In terms of clinical research, the company has built a clinical development and registration team centered on China and the United States with excellent program design capabilities, efficient execution capabilities and regulatory communication capabilities


    In terms of production, as of March 31, 2021, the company has basically completed the construction of the first phase of the production base in Guangzhou.


    In terms of commercialization, as of March 31, 2021, the company has covered hundreds of hospitals across the country, rapidly promoting the market expansion of abutinib in B-cell lymphoma


    Reference source: prospectus (application draft)

    Reference source:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.